Supplements
Riboflavin (vitamin B2): food, deficiency, intake estimates, migraine research, and rare transporter disorders
On this page
Riboflavin is vitamin B2. It is used to make FMN and FAD, coenzymes involved in energy-producing and other cellular reactions. Meeting the vitamin’s nutritional requirement and taking a larger amount to investigate migraine prevention are different uses with different evidence.[1]
Separate the question being asked
| Question | Relevant context |
|---|---|
| Nutritional adequacy | Enough B2 for ordinary physiological needs.[3] |
| Deficiency | A nutritional problem with possible tissue effects.[2] |
| Migraine prevention | A disease-specific intervention.[5] |
| Transporter deficiency | A rare inherited handling disorder.[1] |
The reserve is limited, but the vitamin is not a stimulant
MedlinePlus describes B2 contributing to growth, red-cell production and energy release from carbohydrate, protein and fat. The body maintains only a small reserve, so ongoing intake matters. This does not mean that a concentrated supplement acts like caffeine or that ordinary tiredness proves B2 deficiency. Nutrient participation in a reaction is different from evidence that extra intake changes a person’s performance.[3]
Dairy is one source, rather than the only route
NIH lists milk, eggs, meat, some vegetables and fortified grain products. A person avoiding dairy needs other suitable sources, but that choice alone does not establish a deficiency. The food pattern, portion sizes and any fortification matter together. A supplement label cannot tell whether the rest of someone’s diet meets their nutritional needs.[2]
Light exposure can affect B2 in food
MedlinePlus explains that light can damage riboflavin, one reason food storage matters. Fortification adds a nutrient to a food and is a separate issue from protecting the nutrient already present. This specific vulnerability is not evidence that all cooking or processing makes food nutritionally empty; the food, nutrient and process have to be considered individually.[3]
Risk depends on the wider diet and life stage
NIH describes possible inadequacy in some people avoiding dairy or animal foods, in vegetarian athletes, and during pregnancy or breastfeeding. These are contexts for assessing intake rather than labels that all members of a group are deficient. Nutritional needs can change with life stage, while practical food choices depend on the person’s dietary pattern.[2]
Mouth changes are not a specific home test
NIH describes mouth or lip changes, skin problems and, with marked prolonged deficiency, anemia and other effects. Deficiency may coexist with other nutritional problems. A cracked mouth corner, fatigue or a sore throat can have multiple explanations; matching one symptom to a vitamin advertisement cannot establish the cause or justify a high-dose treatment.[2]
US and European reference systems use different estimates
EFSA’s 2017 final opinion sets adult average requirement and population reference intake at 1.3 and 1.6 milligrams daily, respectively. The US tables shown by NIH use different age- and sex-specific values. These are population frameworks for adequacy, rather than competing personal prescriptions or evidence that one country’s normal diet is inherently deficient.[4][3]
Some research biomarkers are not routine individual tests
NIH discusses erythrocyte glutathione reductase activity, a functional red-cell measurement, while noting interpretive limits and problems in G6PD deficiency. Urinary excretion can reflect recent intake. A research marker, a reference-intake table and a clinical diagnosis therefore provide different information. A high urine value after a supplement is not itself evidence of improved health.[1]
Rare transporter disorders need a separate explanation
NIH describes inherited riboflavin transporter deficiency with neurological, hearing and breathing problems. In that specific disorder, specialist-directed B2 treatment can be important even at amounts unlike ordinary nutritional intake. Evidence for treating an impaired transport mechanism cannot be transferred directly to healthy people seeking better concentration or athletic performance.[1]
Evidence & uncertainty
Migraine research suggests possible benefit, but its limits should appear first: a 2026 review pooled small and varied studies, including some without controls, and reported substantial inconsistency. That supports a qualified explanation of a treatment option, rather than a promise that B2 reliably prevents everyone’s headaches.[6]
Selected-source overview · Independent review pendingPublished questions
Is riboflavin vitamin B2 and a precursor of FMN and FAD?
Selected-source overview · Independent review pending. Read the evidence context.
Yes.[1]
Evidence behind this answer
- Riboflavin: Health Professional Fact Sheet
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Coenzymes, measurements, transporter disorders and upper-limit uncertainty
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can someone obtain riboflavin without dairy foods?
Selected-source overview · Independent review pending. Read the evidence context.
Other foods and fortification can provide B2.[2]
Evidence behind this answer
- Riboflavin: Consumer Fact Sheet
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Foods, intake contexts and deficiency manifestations
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do cracked lips alone diagnose riboflavin deficiency?
Selected-source overview · Independent review pending. Read the evidence context.
A symptom alone does not establish its cause.[2]
Evidence behind this answer
- Riboflavin: Consumer Fact Sheet
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Foods, intake contexts and deficiency manifestations
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can light exposure damage riboflavin in food?
Selected-source overview · Independent review pending. Read the evidence context.
Yes.[3]
Evidence behind this answer
- Riboflavin: Medical Encyclopedia
agency condition or prevention explanation · 2025
Selected relevant original official page passages inspected · January 21, 2025 clinical review: functions, light sensitivity and reference-intake framework
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are nutritional B2 reference values the same as a migraine treatment dose?
Selected-source overview · Independent review pending. Read the evidence context.
They address different questions.[4]
Evidence behind this answer
- Dietary Reference Values for riboflavin
agency scientific opinion · 2017
Selected original indexed final-opinion passages inspected; direct publisher retrieval was intermittent · Final 2017 opinion: requirement derivation, variability and adult values
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the 1998 riboflavin migraine trial include 55 patients over three months?
Selected-source overview · Independent review pending. Read the evidence context.
Yes.[5]
Evidence behind this answer
- Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial
randomized trial · 1998
Original full abstract inspected; full trial and sponsor appraisal pending · 1998: three-month trial, headache-day response and adverse effects
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the 2026 riboflavin migraine review search through all of 2026?
Selected-source overview · Independent review pending. Read the evidence context.
Its search ended in March 2025.[6]
Evidence behind this answer
- The effect of riboflavin on the mean attack frequency, severity, and duration of migraine headaches: a systematic review and dose-response meta-analysis of clinical trials
systematic review · 2026
Original review summary and selected methods/results inspected; no independent full-text appraisal · 2026: March 2025 search, twelve trials, inconsistency and limitations
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does treating rare riboflavin transporter deficiency prove a high-dose benefit for healthy people?
Selected-source overview · Independent review pending. Read the evidence context.
That disease-specific evidence does not establish the healthy-person claim.[1]
Evidence behind this answer
- Riboflavin: Health Professional Fact Sheet
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Coenzymes, measurements, transporter disorders and upper-limit uncertainty
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
The requirement calculation is not a migraine trial
EFSA used the pattern of urinary excretion in response to intake, drawing on four intervention studies, to estimate a level associated with body saturation. It also included an allowance for variability because direct evidence on the spread of requirements was limited. This reasoning concerns nutritional adequacy. It does not establish an effective migraine dose or validate a commercial “maximum energy” target.[4]
A small placebo-controlled migraine study found a signal
Schoenen and colleagues randomized 55 patients for three months in 1998. For headache days, at least a 50% improvement occurred in 59% with riboflavin and 15% with placebo, a 44-percentage-point difference in that study. The study supports a possible preventive effect; it was not a comparison with every established preventive medicine or a test of all headache causes.[5]
Two participants receiving B2 had minor adverse events, diarrhea or increased urination; one placebo participant had abdominal cramps. The short, small trial cannot resolve uncommon harms or long-term benefit. Its abstract does not supply enough information for an independent appraisal of all eligibility and sponsor details.[5]
A newer review adds studies without removing uncertainty
The 2026 review searched through March 15, 2025 and included twelve trials with 749 participants. It found pooled reductions in attack frequency and duration, with inconsistency measures above 90% for both. Very different findings across studies limit confidence in applying one average effect to every patient. Its publication year does not extend its search to all of 2026.[6]
Some included studies lacked control groups or had small samples. The authors’ quality labels are their appraisal, not an independent Atlas grade. The dose-response analysis cannot, by itself, determine a person’s safest or best dose. Pediatric findings, full study tables and contemporary treatment comparisons require further appraisal.[6]
No established upper limit does not establish unlimited safety
NIH could not set an upper intake limit from available safety evidence. Its older migraine-guideline citations do not amount to a current recommendation.[1]
References
- Riboflavin: Health Professional Fact Sheet
Agency condition or prevention explanation
NIH Office of Dietary Supplements · Content/publication date: not stated
Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
Cited sections: Coenzymes, measurements, transporter disorders and upper-limit uncertaintyOlder migraine-guideline citations are not presented as current recommendations.
- Riboflavin: Consumer Fact Sheet
Agency condition or prevention explanation
NIH Office of Dietary Supplements · Content/publication date: not stated
Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
Cited sections: Foods, intake contexts and deficiency manifestations - Riboflavin: Medical Encyclopedia
Agency condition or prevention explanation
A.D.A.M. clinical editors / MedlinePlus · Content/publication date: 2025
Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
Cited sections: January 21, 2025 clinical review: functions, light sensitivity and reference-intake framework - Dietary Reference Values for riboflavin
Agency scientific opinion
EFSA NDA Panel · Content/publication date: 2017
Accessed: 2026-10-09 UTC · Selected original indexed final-opinion passages inspected; direct publisher retrieval was intermittent
Cited sections: Final 2017 opinion: requirement derivation, variability and adult valuesPrimary opinion and its hosted reproductions represent one source.
- Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial
Randomized trial
Schoenen J, Jacquy J and Lenaerts M · Content/publication date: 1998
Accessed: 2026-10-09 UTC · Original full abstract inspected; full trial and sponsor appraisal pending
Cited sections: 1998: three-month trial, headache-day response and adverse effects - The effect of riboflavin on the mean attack frequency, severity, and duration of migraine headaches: a systematic review and dose-response meta-analysis of clinical trials
Systematic review
Amini S and colleagues · Content/publication date: 2026
Accessed: 2026-10-09 UTC · Original review summary and selected methods/results inspected; no independent full-text appraisal
Cited sections: 2026: March 2025 search, twelve trials, inconsistency and limitationsOriginal full abstract inspected; no independent study-level or dose-response appraisal.
Scope & review
- Population
- Readers exploring B2 nutrition; migraine and inherited transporter populations are distinguished
- Exposure or intervention
- Food, nutrient status, reference-intake assumptions and selected disease-specific treatment evidence
- Comparison
- Source-specific symptom, care, screening or comparator settings
- Outcomes
- Nutritional adequacy, symptoms, headache frequency/duration and adverse effects
- Timeframe
- Regular dietary intake; selected three-month trial and review search through March 2025
- Jurisdiction
- Selected US/UK agency and US/European professional guidance; jurisdiction and eligibility differences are labeled
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-09 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
What this article still leaves open
- Current migraine guideline recommendations, pediatric results and full trial-level benefit/safety and sponsorship appraisal remain outstanding.
- Rare transporter syndromes, biomarker validation and special nutritional populations need dedicated coverage.
- Qualified review, personal deficiency diagnosis and supplement or migraine regimens are not supplied.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.